The main adverse effect is anaphylaxis (a life-threatening systemic allergic reaction), with a rate of occurrence of 1 to 2 patients per 1,000. Limited studies are available to confirm whether<unk>  increases the risk of developing cardiovascular (CV) or cerebrovascular disease (CBV). Cohort and randomised controlled studies have shown that the risk of developing CV/CBV disease is around 20-32% higher in patients taking<unk>  compared to those not taking<unk> . Additional multi-national, longitudinal studies with increased subject numbers are required to provide further clarification into the relationship and clinical significance between<unk>  and CV/CBV disease. Due to the severity of CV/CBVs side effects, clinicians and health care providers should continue to remain vigilant and monitor side effects when treating patients with<unk> . IgE may play an important role in the immune system's recognition of cancer cells. Therefore, indiscriminate blocking of IgE-receptor interaction with<unk>  may have unforeseen risks. The data pooled in 2003 from the earlier phase I to phase III clinical trials showed a numeric imbalance in malignancies arising in<unk>  recipients (0.5%) compared with control subjects (0.2%). A 2012 study found that a causal link with cancer was unlikely.
Omalizumab
Crizanlizumab
Reslizumab
Lirentelimab
Tildrakizumab
Risankizumab
Bebtelovimab
Brolucizumab